阅读说明：本技术 一种治疗健忘的组分配方 (Component formula for treating amnesia ) 是由 武密山 武博文 于 2019-09-05 设计创作，主要内容包括：本发明公开了一种治疗健忘的组分配方,所述的药物配方包含有细叶远志皂苷(C36H56O12)、人参皂苷Rg1(C42H72O14)和茯苓糖(pachymose)、菖蒲素(acoradin),以及药学上可接受的辅料,细叶远志皂苷(C36H56O12)、人参皂苷Rg1(C42H72O14)和茯苓糖(pachymose)、菖蒲素(acoradin)的摩尔比为1:2.5-5)。所述的药物配方能够显著治疗健忘症。能改善记忆力、增强智力,对失眠多梦、健忘、惊悸、神志恍惚、精神衰弱、记忆障碍,效果明显优于同等剂量的细叶远志皂苷(C36H56O12)、人参皂苷Rg1(C42H72O14)或茯苓糖(pachymose)、菖蒲素(acoradin)单独用药,说明四者联合使用后,具有显著的协同增效作用,毒副作用低,临床前景应用良好。(The invention discloses a component formula for treating amnesia, which comprises tenuifolin (C36H56O12), ginsenoside Rg1(C42H72O14), pachymase (pachymese), calamus (aconadin) and pharmaceutically acceptable auxiliary materials, wherein the molar ratio of the tenuifolin (C36H56O12), the ginsenoside Rg1(C42H72O14), the pachymase (pachymese) and the calamus (aconadin) is 1: 2.5-5. The medicine formula can be used for remarkably treating amnesia. The composition can improve memory and enhance intelligence, has obviously better effects than the independent administration of tenuifolin (C36H56O12), ginsenoside Rg1(C42H72O14) or pachymase and acorarin (pachyme) with the same dosage on insomnia, dreaminess, amnesia, pavor, absent mindedness, psychasthenia and dysmnesia, and shows that the composition has obvious synergistic effect after the four are jointly used, low toxic and side effects and good clinical prospect application.)

1. The formula of the amnesia treating component is characterized in that: the formula comprises saponin extract and antibacterial extract, wherein the saponin extract is tenuifolin (C)₃₆H₅₆O₁₂) And ginsenoside Rg1 (C)₄₂H₇₂O₁₄) The antibacterial extracts are pachymase (pachymeose) and calamus (acoradin), and the mass ratio of the saponin extracts to the antibacterial extracts is 1: 2.5-5.

2. The composition formula for treating amnesia according to claim 1, wherein: the mol ratio of the tenuifolin to the ginsenoside is 1: 1.

3. the composition formula for treating amnesia according to claim 1, wherein: the molar ratio of pachyman to calamus is 1: 1.

4. the composition formula for treating amnesia according to claim 1, wherein: the purity of the saponin extract is more than or equal to 95 percent, and the purity of the antibacterial extract is more than or equal to 97 percent.

5. The composition formula for treating amnesia according to claim 1, wherein: the formula comprises pharmaceutically acceptable auxiliary materials, wherein the auxiliary materials are selected from sodium hyaluronate, sodium alginate, chitosan or collagen.

6. The composition formula for treating amnesia according to claim 1, wherein: the tenuifolin (C)₃₆H₅₆O₁₂) Ginsenoside Rg1 (C)₄₂H₇₂O₁₄) The administration dosage of (A) is 10-100mg/kg, and the administration dosage of pachymase (pachymese) and calamus (acoradin) is 15-150 mg/kg.

7. The composition formula for treating amnesia according to claim 1, wherein: the medicine formula is oral preparation or injection.

8. The composition formula for treating amnesia according to claim 7, wherein: the oral preparation is hard capsule, soft capsule, sustained-release capsule, coated tablet, powder, granule, dripping pill, water-honeyed pill, syrup or oral liquid; the injection is in a solution type, a suspension type, an emulsion type or freeze-dried powder type.

Technical Field

The invention belongs to the technical field of pharmaceutical formulations, and particularly relates to a component formulation for treating amnesia (temporary memory disorder).

Background

Amnesia is marked by hypomnesis, easy forgetting in case of deficiency of brain marrow, lack of nourishment of brain marrow, or disturbed consciousness, unlike those with biological retardation and insufficiency of natural resources, the location of the disease in the brain, related to deficiency of heart-spleen and kidney, western medicine, encephalatrophy, cerebral trauma sequelae, cerebrovascular diseases, various cerebral degenerative diseases such as Parkinson's disease, central nervous system infectious diseases such as encephalitis, drug abuse, such as hypnotic and sedative drugs, anticonvulsants, antipsychotic drugs, antidepressants, and alcohol abuse.

Amnesia is a dementia syndrome characterized by cognitive impairment due to ischemic or hemorrhagic cerebral infarction, and is clinically manifested by impaired cognitive functions such as language, memory, and visuospatial skills. With the aggravation of the aging phenomenon of the population in China, the frequent occurrence of cerebrovascular diseases and the improvement of the amnesia diagnosis level, the amnesia morbidity rate is on the trend of increasing year by year, and according to statistics, the amnesia morbidity rate in the population over 55 years old in China is 0.8 percent, so that the life quality and even the life of a patient are seriously threatened, and huge economic and mental burdens are brought to the society and families. To date, although there are some clinical studies on the treatment of amnesia, there is still no known effective treatment method, so that the search for new amnesia treatment drugs is of great significance for the prevention of amnesia and the improvement of prognosis.

Disclosure of Invention

The invention aims to provide a component formula for treating amnesia (temporary dysmnesia) and application thereof, and polygalasaponin C is combined₃₆H₅₆O₁₂) Ginsenoside Rg1 (C)₄₂H₇₂O₁₄) And pachymase (pachymeose) and acorarin (acoradin) as effective components for treating amnesia (temporary memory disorder) to exert synergistic effect.

The technical scheme adopted by the invention is as follows:

a composition formula for treating amnesia comprises saponin extract and antibacterial extract, wherein the saponin extract is tenuifolin (C)₃₆H₅₆O₁₂) And ginsenoside Rg1 (C)₄₂H₇₂O₁₄) The antibacterial extracts are pachymase (pachymeose) and calamus (acoradin), and the mass ratio of the saponin extracts to the antibacterial extracts is 1:2.5-5

Specifically, the molar ratio of the tenuifolin to the ginsenoside is 1: 1.

further, the molar ratio of pachyman to calamus is 1: 1.

specifically, the purity of the saponin extract is more than or equal to 95%, and the purity of the antibacterial extract is more than or equal to 97%.

Further, the formula comprises pharmaceutically acceptable auxiliary materials, wherein the auxiliary materials are selected from sodium hyaluronate, sodium alginate, chitosan or collagen.

Specifically, the tenuifolin (C)₃₆H₅₆O₁₂) Ginsenoside Rg1 (C)₄₂H₇₂O₁₄) The administration dosage of (A) is 10-100mg/kg, and the administration dosage of pachymase (pachymese) and calamus (acoradin) is 15-150 mg/kg.

Specifically, the pharmaceutical formulation is an oral preparation or an injection.

Further, the oral preparation is a hard capsule, a soft capsule, a sustained-release capsule, a sugar-coated tablet, powder, granules, a dropping pill, a water-honeyed pill, syrup or oral liquid; the injection is in a solution type, a suspension type, an emulsion type or freeze-dried powder type.

The invention has the following advantages:

the invention provides a component formula for treating amnesia (temporary dysmnesia), which contains polygalasaponin C of a first type of tenuifolin₃₆H₅₆O₁₂) Ginsenoside Rg1 (C)₄₂H₇₂O₁₄) (ii) a And pachymase II (pachymeose), calamus (acoradin), and pharmaceutically acceptable adjuvants. The medicine formula can obviously improve amnesia (temporary dysmnesia) and has obviously better effect than the first type tenuifolin (C) with the same dosage₃₆H₅₆O₁₂) Ginsenoside Rg1 (C)₄₂H₇₂O₁₄) (ii) a Or the second type pachymase (pachymeose) and the calamus (acoradin) are independently used, which shows that the combination has obvious synergistic effect, low toxic and side effects and good clinical prospect and application after combined compatibility.

Drawings

FIG. 1 Effect of different dose groups on the Effect of brain ischemia (leading to amnesia) on the concentration of Excitatory Amino Acids (EAAs) neurotransmitter (Glu) in rat striatal region with time

FIG. 2 Effect of different dose groups on the Effect of brain ischemia (leading to amnesia) on the concentration of Excitatory Amino Acids (EAAs) neurotransmitter (Asp) in rat striatal region over time

FIG. 3 Effect of different dose groups on the change of Inhibitory Amino Acid (IAAs) neurotransmitter (GABA) concentration in rat striatal region with cerebral ischemia (causing amnesia) with time

FIG. 4 Effect of different dose groups on the change of the concentration of Inhibitory Amino Acids (IAAs) neurotransmitter (Gly) in rat striatal region with cerebral ischemia (causing amnesia) with time

Detailed Description

The invention will be further described with reference to the accompanying drawings in which:

the invention relates to a component formula for treating amnesia (temporary dysmnesia), which comprises polygalasaponin C of a first type of tenuifolin₃₆H₅₆O₁₂) Ginsenoside Rg1 (C)₄₂H₇₂O₁₄) (ii) a And pachymase (pachymeose) class II, calamus (acoradin). Polygala tenuifolia Willd saponin C₃₆H₅₆O₁₂) Ginsenoside Rg1 (C)₄₂H₇₂O₁₄) (ii) a And pachymase (pachymeose) of the second type and acoradin (acoradin) in a molar ratio of (1:2.5) - (1: 5). Polygala tenuifolia Willd saponin C₃₆H₅₆O₁₂) Ginsenoside Rg1 (C)₄₂H₇₂O₁₄) The purity of the compound is more than or equal to 95 percent, and the purity of the second type pachymose (pachymeose) and calamus (acoradin) is more than or equal to 97 percent.

The medicine formula comprises pharmaceutically acceptable auxiliary materials. The adjuvant is selected from sodium hyaluronate, sodium alginate, chitosan or collagen.

Polygala tenuifolia Willd saponin (C) of the first kind₃₆H₅₆O₁₂) Ginsenoside Rg1 (C)₄₂H₇₂O₁₄) (ii) a Can be combined with pachymase and acorarin to prepare the effective components of medicine for treating amnesia. Polygala tenuifolia Willd saponin C₃₆H₅₆O₁₂) Ginsenoside Rg1 (C)₄₂H₇₂O₁₄) The administration dose of the drug is 10-100mg/kg, and the administration doses of the second type pachymose (pachymese) and the calamus (acoradin) are 15-150mg/kg respectively.

The medicine formula is oral preparation or injection. The oral preparation is hard capsule, soft capsule, sustained-release capsule, coated tablet, powder, granule, dripping pill, water-honeyed pill, syrup or oral liquid; the injection is in a solution type, a suspension type, an emulsion type or freeze-dried powder type.